Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Improving cancer diagnosis and care : patient access to oncologic imaging and pathology expertise and technologies : proceedings of a workshop / / Erin Balogh, Margie Patlak, and Sharyl J. Nass, rapporteurs
| Improving cancer diagnosis and care : patient access to oncologic imaging and pathology expertise and technologies : proceedings of a workshop / / Erin Balogh, Margie Patlak, and Sharyl J. Nass, rapporteurs |
| Pubbl/distr/stampa | Washington, District of Columbia : , : The National Academies Press, , [2018] |
| Descrizione fisica | 1 online resource (xx, 72 pages) : illustrations |
| Disciplina | 616.994075 |
| Soggetto topico | Cancer - Diagnosis |
| ISBN |
0-309-47831-6
0-309-47829-4 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Intro -- Front Matter -- Workshop Overview -- Current Diagnostic Challenges in Cancer Care -- Ensuring the Quality and Accessibility of Diagnostic Expertise and Technologies -- Quality Improvement Efforts -- Integration and Collaboration of Specialties -- Wrap-Up -- References -- Appendix A: Statement of Task -- Appendix B: Workshop Agenda. |
| Record Nr. | UNINA-9910813366603321 |
| Washington, District of Columbia : , : The National Academies Press, , [2018] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Liquid Biopsy in Cancer Patients : The Hand Lens for Tumor Evolution / / edited by Antonio Russo, Antonio Giordano, Christian Rolfo
| Liquid Biopsy in Cancer Patients : The Hand Lens for Tumor Evolution / / edited by Antonio Russo, Antonio Giordano, Christian Rolfo |
| Edizione | [1st ed. 2017.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Humana, , 2017 |
| Descrizione fisica | 1 online resource (XI, 214 p. 41 illus., 40 illus. in color.) |
| Disciplina | 616.994075 |
| Collana | Current Clinical Pathology |
| Soggetto topico |
Pathology
Oncology Oncology |
| ISBN | 3-319-55661-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Precision Medicine: Are We There? -- Clonal Cancer Evolution and Intra-tumor Heterogeneity -- Tissue vs. Liquid Biopsy: Opposite or Complementary? -- Technical Aspects for the Evaluation of Circulating Tumor Cells (CTCs) -- Technical Aspects for the Evaluation of Circulating Nucleic Acids (CNA): Circulating Tumor DNA (ctDNA) and Circulating MicroRNAs -- Technical Aspects for the Evaluation of Exosome and their Content -- Liquid Biopsy in Breast Cancer -- Liquid Biopsy in Head and Neck Cancers -- Liquid Biopsy in NSCLC -- Liquid Biopsy in Gastric Cancer -- Liquid Biopsy in Pancreatic Cancer -- Liquid Biopsy in HCC -- Liquid Biopsy in CRC -- Liquid Biopsy in GIST -- Liquid Biopsy in Kidney Cancer -- Liquid Biopsy in Melanoma. |
| Record Nr. | UNINA-9910254660203321 |
| Cham : , : Springer International Publishing : , : Imprint : Humana, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
microRNA: Cancer : From Molecular Biology to Clinical Practice / / edited by Gaetano Santulli
| microRNA: Cancer : From Molecular Biology to Clinical Practice / / edited by Gaetano Santulli |
| Edizione | [1st ed. 2015.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2015 |
| Descrizione fisica | 1 online resource (241 p.) |
| Disciplina | 616.994075 |
| Collana | Advances in Experimental Medicine and Biology |
| Soggetto topico |
Molecular biology
Cell physiology Cancer research Biochemistry Human physiology Molecular Medicine Cell Physiology Cancer Research Animal Biochemistry Human Physiology |
| ISBN | 3-319-23730-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1) microRNA: the master key to precision medicine -- 2) MICRORNAS IN THE MALIGNANT TRANSFORMATION PROCESS -- 3) microRNA and chronic lymphocytic leukemia -- 4) microRNA and malignant lymphoma -- 5) microRNA and gastrointestinal stromal cancer -- 6) microRNA and pancreatic cancer -- 7) microRNA and colorectal cancer -- 8) microRNA and prostate cancer -- 9) Ovarian cancer -- 10) microRNA and breast cancer -- 11) microRNA and soft tissue sarcoma -- 12) microRNA and bone cancer. |
| Record Nr. | UNINA-9910298452003321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Molecular Biomarkers for Cancer Diagnosis and Therapy
| Molecular Biomarkers for Cancer Diagnosis and Therapy |
| Autore | Sobti Ranbir Chander |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore Pte. Limited, , 2024 |
| Descrizione fisica | 1 online resource (770 pages) |
| Disciplina | 616.994075 |
| Altri autori (Persone) |
SugimuraHaruhiko
SobtiAastha |
| Soggetto topico |
Early Detection of Cancer
Biomarkers, Tumor Neoplasms - diagnosis Neoplasms - therapy |
| ISBN | 9789819937462 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Introduction -- References -- Contents -- Editors and Contributors -- 1: Molecular Biomarkers of Cancer and Their Diagnostic Applications -- 1.1 Introduction -- 1.2 Advancement and Challenges in Cancer Biomarker Science -- 1.2.1 Specificity of the Biomarkers -- 1.2.2 Screening Strategies -- 1.2.3 Inheritance of Particular Cancer -- 1.2.4 Identification and Monitoring of Biomarkers -- 1.3 Clinical Implications of Various Cancer Biomarkers -- 1.3.1 DNA Methylation as an Epigenetic Cancer Biomarker -- 1.3.2 Noncoding RNAs (MicroRNAs) as Cancer Biomarkers -- 1.3.3 Protein Biomarkers in various cancers -- 1.3.4 Fusion Genes in Cancer Diagnostics -- 1.4 Concluding Remarks -- References -- 2: Statistical Models in Cancer Management -- 2.1 Introduction -- 2.2 Markov Framework Model for Cancer Screening -- 2.3 Analytical Models -- 2.4 The Standardized Regression Model in Cancer -- 2.5 Ordinary Differential Equations (ODEs) -- 2.6 PARADIGM -- 2.6.1 Generalized Diagram of Working of PARADIGM -- 2.7 Logistic Model -- 2.8 Cox Survival Model -- 2.9 Continuous Growth Model -- 2.10 Conclusion -- References -- 3: Cancer: Epidemiology, Racial, and Geographical Disparities -- 3.1 Epidemiology -- 3.1.1 Cancer and Age Group -- 3.1.2 Cancer and Gender -- 3.1.3 Cancer Type and Risk Factor -- 3.1.4 Cancer and Sex Ratio -- 3.1.5 Cancer and Mortality Rate -- 3.2 Racial Disparities -- 3.3 Geographical Disparities -- 3.3.1 Lung and Bronchus -- 3.3.2 Colon and Rectum -- 3.3.3 Female Breast -- 3.3.4 Prostate -- 3.3.5 Stomach -- 3.3.6 Liver -- 3.3.7 Oesophagus -- 3.3.8 Cervix Uteri -- 3.4 Conclusion -- References -- 4: Protein Markers in the Detection of Cancer -- 4.1 Introduction -- 4.1.1 Tumor Markers Used in Cancer -- 4.1.1.1 Two Types of Tumor Markers Are Used Clinically -- 4.2 Circulating Tumor Markers -- 4.3 Tumor Tissue Markers.
4.3.1 Some Important Tumor Markers Are Currently Being Used for Detection of Cancer -- 4.3.2 Proteomic Signatures of Cancer -- 4.3.3 Heat Shock Proteins -- 4.3.4 Carcino Embryonic Antigen -- 4.3.5 Tissue Inhibitor of Matrix Metalloproteinase 1 -- 4.3.6 Enzymes -- 4.3.7 MiRNAs -- 4.3.8 Cytokines -- 4.3.9 Chemokines -- 4.3.10 Stem Cell Associated Markers -- 4.3.10.1 Test Routinely Used for Cancer Detection -- 4.3.11 Prostate-Specific Antigen (PSA) -- 4.3.12 Liquid Biopsy Based Assays Test -- 4.3.12.1 Future Prospective of Protein Markers in Cancer Treatment -- References -- 5: Computer-Aided Diagnosis System for Early Detection of Malignant Tissues -- 5.1 Introduction -- 5.2 CAD for Different Types of Cancers -- 5.2.1 Prostate Cancer -- 5.2.2 Cervical Cancer -- 5.2.3 Pancreatic Cancer -- 5.2.4 Colon Polyps -- 5.2.5 Kidney -- 5.2.6 Skin Cancer -- 5.2.7 Breast Cancer -- 5.3 Conclusion -- References -- 6: Molecular Mechanisms of Oncogenesis -- 6.1 Oncogenesis: A Multistep Process -- 6.1.1 Cell-Cycle Dysregulation -- 6.1.2 Alteration in Apoptosis, Senescence, and Cell Growth Arrest -- 6.1.3 Autonomous to Growth Factors Signaling -- 6.1.4 Metastasis and Invasion -- 6.2 Factors Triggering Oncogenesis -- 6.2.1 Carcinogenic Chemicals -- 6.2.2 Ionizing and Ultraviolet Radiation -- 6.2.3 Oncogenic Viruses -- 6.2.4 The Tumor Microenvironment -- 6.2.5 Chemotherapeutic Agents -- 6.2.6 Tumor Promoters -- 6.3 Molecular Mechanisms Underlying the Process of Oncogenesis -- 6.3.1 Activation of Oncogenes -- 6.3.2 Inactivation of Tumor-Suppressor Genes -- 6.3.3 Epigenetic Alterations -- 6.3.4 OncomiR (microRNA Genes) -- 6.3.5 Mutations in DNA Repair Genes/Genomic Stability Genes -- 6.3.6 Defects in Cell-Cycle Regulation -- References -- 7: Application of CRISPR in Cancer Research and Treatment -- 7.1 Introduction -- 7.2 CRISPR/Cas9 in Cancer Research. 7.2.1 Generation of Cancer Models -- 7.2.2 Target Discovery and Validation in Oncology -- 7.3 CRISPR/Cas9 for Diagnostics -- 7.4 Applications of CRISPR/Cas9 in Cancer Treatment -- 7.4.1 CRISPR/Cas9 System in CAR-T Cell Immunotherapy -- 7.4.2 CRISPR/Cas9 for Inhibition of Immune Checkpoint Signaling -- 7.5 Conclusions and Perspectives -- References -- 8: Nanobiosensing Platforms for Early Detection of Cancer -- 8.1 Introduction -- 8.2 Conventional Methods of Cancer Detection and Challenges -- 8.3 Biomarkers for Cancer Detection -- 8.3.1 Nanoparticle-Based Biosensor Platforms for Cancer Detection -- 8.4 Gold Nanoparticle-Based Biosensing Probe for Cancer Detection -- 8.5 Carbon-Based Nanobiosensors -- 8.6 Quantum Dot-Based Cancer Biosensing and Bioimaging Platform -- 8.6.1 Nanoparticle-Based Multiplexed Biosensing Assay -- 8.7 Conclusion -- References -- 9: Bionanotechnological Strategies and Tools for Cancer Prediction, Prevention and Therapy -- 9.1 Cancer Burden and Impact -- 9.2 Oral Cancer and Burden -- 9.2.1 Oral Cancer: Screening Accuracy, Efficacy and Harms -- 9.2.2 Oral Cancer: Role of Nanotechnology -- 9.2.3 Clinical Diagnosis: Oral Cancer -- 9.2.4 Management: Oral Cancer -- 9.2.5 Economics of Nano Strategies: Oral Cancer -- 9.3 Colon Cancer and Burden -- 9.3.1 Colon Cancer: Screening Accuracy, Efficacy and Harms -- 9.3.2 Colon Cancer: Role of Nanotechnology -- 9.3.3 Clinical Diagnosis: Colon Cancer -- 9.3.4 Management: Colon Cancer -- 9.3.5 Economics of Nano Strategies: Colon Cancer -- 9.4 Challenges in Bionanotechnological Interventions -- 9.5 Way Forward -- 9.6 Conclusion -- References -- 10: Central Nervous System Tumors -- 10.1 Part I: Gliomas -- 10.1.1 Background -- 10.1.2 Anatomical Location -- 10.1.3 Epidemiology -- 10.1.4 Clinical Presentation -- 10.1.5 History and Physical Examination -- 10.1.6 Investigations. 10.1.6.1 MR Spectroscopy -- 10.1.6.2 PET-CT Scan -- 10.1.7 Risk Factors -- 10.1.7.1 Environmental Factors -- 10.1.7.2 Hereditary Factors -- 10.1.8 Histology -- 10.1.9 Management -- 10.1.9.1 Low-Grade Gliomas (LGG) -- 10.1.9.1.1 Surgery -- Circumscribed Low-Grade Gliomas -- Infiltrative or Diffuse Low-Grade Gliomas -- 10.1.9.1.2 Radiotherapy (RT) -- Adjuvant Radiotherapy Alone -- Adjuvant Radiotherapy and Chemotherapy -- Dose/Fractionation -- Advanced Radiotherapy Modalities -- 10.1.10 Anaplastic Gliomas -- 10.1.11 Anaplastic Astrocytomas -- 10.1.12 Anaplastic Oligodendroglial Tumors -- 10.1.13 Grade IV Glial Tumors -- 10.1.14 Immunotherapy -- 10.1.15 Tumor Treating Fields -- 10.1.16 Elderly Patients with GBM -- 10.1.17 Pseudoprogression in Glioma -- 10.1.18 Recurrent Malignant Gliomas -- 10.1.18.1 Surgery -- 10.1.18.2 Reirradiation -- 10.1.18.2.1 Brachytherapy -- 10.1.18.2.2 Radiosurgery -- 10.1.18.2.3 Fractionated EBRT -- 10.1.18.2.4 Systemic Therapy -- 10.1.19 Irradiation Techniques and Toxicities -- 10.1.20 Toxicities of Radiotherapy -- 10.1.21 Radiotherapy for Grade III Gliomas -- 10.2 Part II: Other CNS Tumors -- 10.2.1 Meningioma -- 10.2.2 Clinical Features -- 10.2.3 Radiological Features -- 10.2.4 Histopathology -- 10.2.5 Management -- 10.2.6 Primitive Neuroectodermal (PNET) Tumors -- 10.2.7 Treatment -- 10.2.8 Vestibular Schwannoma -- 10.2.9 Pituitary Adenoma -- 10.2.10 Craniopharyngioma -- 10.2.11 Glomus Jugulare -- 10.2.12 Pineal Region Tumors -- 10.2.13 Ependymoma -- 10.2.14 Metastases -- References -- 11: Biomedical Approaches in the Research and Management of Head and Neck Squamous Cell Carcinoma -- 11.1 Introduction -- 11.2 Risk Factors for the Development of HNSCC -- 11.3 Overview of HNSCC Tumorigenesis and Biology -- 11.4 miRNA Deregulation in HNSCC and Circulating miRNAs in Liquid Biopsies -- 11.5 Machine-Learning (ML) Techniques. 11.6 Raman Spectroscopy (RS) -- 11.7 Organoid Models (Three-Dimensional [3D] Cancer Cell Cultures) -- 11.8 Conclusions -- References -- 12: Applications of Molecular Biology and Biomedical Advances in Ocular Oncology -- 12.1 Introduction -- 12.2 Retinoblastoma -- 12.2.1 Introduction -- 12.2.2 Genetics -- 12.2.3 Genomic Landscape in Retinoblastoma -- 12.2.4 Etiopathogenesis -- 12.2.5 Cell of Origin -- 12.2.6 Development of Three-Dimensional Organoid Models -- 12.2.7 Techniques to Test RB1 Mutations -- 12.2.8 New Heritable Marker in Retinoblastoma: p16INK4a -- 12.2.9 Surging Potential of Liquid Biopsy -- 12.2.10 Oncolytic Virus VCN-01: A New Ray of Hope in RB Treatment -- 12.2.11 Role of Negative Transcriptional Regulators: MicroRNAs (miRNAs) -- 12.2.11.1 Introduction -- 12.2.11.2 miRNAs in Retinoblastoma -- 12.2.12 p53 in Peripheral Blood of RB Patients as a Biomarker -- 12.2.13 Novel Targets for RB Treatment -- 12.2.14 Noncoding RNAs in RB -- 12.2.15 Prenatal Diagnostic Testing -- 12.2.16 Autofluorescence in RB -- 12.2.17 PDT for RB In Vitro Studies -- 12.2.18 Spectral Domain Optical Coherence Tomography in Retinoblastoma -- 12.2.19 Optical Coherence Tomography Angiography in RB -- 12.3 Uveal Melanoma -- 12.3.1 Introduction -- 12.3.2 Genetics of Uveal Melanoma -- 12.3.2.1 Genetic Prognostic Tests -- 12.3.3 Current Innovative Therapeutic Options for Metastatic Tumors -- 12.3.3.1 Targeted Therapy -- 12.3.3.2 Immunotherapy -- 12.3.3.2.1 Checkpoint Inhibitors -- 12.3.3.2.2 Innovative Immune-Based Approaches -- 12.3.3.2.3 Epigenetic Approach -- 12.3.4 Conclusion -- 12.4 Primary Vitreoretinal Lymphoma -- 12.4.1 Introduction -- 12.4.2 Genetics of Vitreoretinal Lymphoma -- 12.4.3 Diagnosis of Vitreoretinal Lymphoma -- 12.4.4 Advances in the Treatment of Vitreoretinal Lymphoma -- 12.5 Conclusion -- References -- 13: Molecular Biomarkers of Oral Cancer. 13.1 Introduction. |
| Record Nr. | UNINA-9910869175103321 |
Sobti Ranbir Chander
|
||
| Singapore : , : Springer Singapore Pte. Limited, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy / / edited by Yutaka Shimada, Katsuhiko Yanaga
| Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy / / edited by Yutaka Shimada, Katsuhiko Yanaga |
| Edizione | [1st ed. 2018.] |
| Pubbl/distr/stampa | Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2018 |
| Descrizione fisica | 1 online resource (VIII, 156 p. 42 illus., 35 illus. in color.) |
| Disciplina | 616.994075 |
| Collana | Current Human Cell Research and Applications |
| Soggetto topico |
Oncology
Cancer - Treatment Clinical biochemistry Cancer Cancer Therapy Medical Biochemistry Cancer Biology |
| ISBN | 981-10-6469-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. Molecular biology of lung cancer in relation to precision medicine -- 2. Molecular diagnosis and targeting for breast cancer -- 3. Clinical application of stem cell biology in esophageal cancer -- 4. Molecular diagnosis and targeted therapy for gastric cancer -- 5. Molecular diagnosis and targeted therapy for colorectal cancer -- 6. Molecular and immunologic targets for the treatment of hepatocellular carcinoma -- 7. Molecular diagnosis and targeting for biliary tract cancer -- 8. Molecular analysis for therapeutic targets of pancreatic cancer -- 9. Molecular targeted therapy and diagnosis for gastroenteropancreatic neuroendocrine tumors. |
| Record Nr. | UNINA-9910300444603321 |
| Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2018 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Molecular surgical pathology / / Liang Cheng, John N. Eble, editors
| Molecular surgical pathology / / Liang Cheng, John N. Eble, editors |
| Edizione | [1st ed. 2013.] |
| Pubbl/distr/stampa | New York, : Springer, c2013 |
| Descrizione fisica | 1 online resource (441 p.) |
| Disciplina | 616.994075 |
| Altri autori (Persone) |
ChengLiang
EbleJohn N |
| Soggetto topico |
Pathology, Molecular
Pathology, Surgical |
| ISBN |
1-283-84903-8
1-4614-4900-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Molecular Pathology of Colorectal Cancer -- Molecular Pathology of Pancreatic Cancer -- Molecular Pathology of Liver Tumors -- Molecular Pathology of Gallbladder Cancer -- Molecular Pathology of Lung Cancers -- Molecular Pathology of Breast Cancer -- Molecular Pathology of Ovarian Cancer -- Molecular Pathology of Endometrial Cancer -- Molecular Pathology of Kidney Tumors -- Molecular Pathology of Prostate Cancer -- Molecular Pathology of Urinary Bladder Cancer -- Molecular Pathology of Testicular Cancer -- Molecular Pathology of Cutaneous Melanoma and Nonmelanoma Skin Cancer -- Molecular Pathology of Head and Neck Cancer -- Molecular Pathology of Soft Tissue and Bone Tumors -- Molecular Pathology of the Central Nervous System -- Molecular Pathology of Endocrine Cancers. |
| Record Nr. | UNINA-9910438012003321 |
| New York, : Springer, c2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Multimodal optical diagnostics of cancer / / Valery V. Tuchin, JuÌrgen Popp, Valery Zakharov, editors
| Multimodal optical diagnostics of cancer / / Valery V. Tuchin, JuÌrgen Popp, Valery Zakharov, editors |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2020] |
| Descrizione fisica | 1 online resource (XX, 597 p. 193 illus., 153 illus. in color.) |
| Disciplina | 616.994075 |
| Soggetto topico |
Cancer - Imaging
Biomedical engineering Cancer - Diagnosis |
| ISBN | 3-030-44594-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction: Enhancing Detection and Early Cancer Recognition with Multimodal Optical Imaging and Spectral Analysis -- Malignant tissue optics -- Optical clearing of biological tissues: prospects of application for multimodal cancer diagnostics -- Multiparametric analysis of tumor using microscopic fluorescence imaging -- NIRS for brain cancer detection -- Exhaled air analysis using wideband wave number tuning range infrared laser photoacoustic spectroscopy -- Multispectral and multimodal fiber sensing in oncology -- Diagnostics of pigmented skin tumors based on laser-induced autofluorescence and diffuse reflectance spectroscopy -- Raman-based molecular imaging and analytics, Surface-enhanced Raman spectroscopy for cancer diagnostics, Raman/CARS/TPEF/SHG multimodal imaging as a pathological screening tool -- In vivo Multimodal Optical Biopsy of Skin Cancer -- Raman hyperspectroscopy and advanced statistics for cancer differentiation -- Intraoperative brain cancer detection with Label-Free Multimodal Optical Spectroscopy -- 3D confocal Raman and two-photon microscopy imaging of the skin -- Multimodal Optical Imaging for Cancer Detection -- Multidimentional and Multilevel Imaging: towards 3D histopathology -- Multimodal OCT for malignancy imaging -- Multimodal texture analysis of OCT tumor images -- Hyperspectral imaging and cancer detection -- Multimodal Deep Imaging using SORS and OCT: for precise cancer boundary detection -- FLIM imaging combined with MRI -- Terahertz spectroscopy of human brain tumor. |
| Record Nr. | UNINA-9910424632203321 |
| Cham, Switzerland : , : Springer, , [2020] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Nanomedicine for cancer diagnosis and therapy / / Arshi Malik, Sarah Afaq and Mohammed Tarique (editors)
| Nanomedicine for cancer diagnosis and therapy / / Arshi Malik, Sarah Afaq and Mohammed Tarique (editors) |
| Pubbl/distr/stampa | Gateway East, Singapore : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (251 pages) |
| Disciplina | 616.994075 |
| Soggetto topico |
Nanomedicine
Cancer - Treatment - Technological innovations Nanomedicina Oncologia Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-15-7564-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- About the Editors -- 1: Nanoparticles for Cancer Therapy -- 1.1 Introduction -- 1.1.1 Cancer and its Types -- 1.1.2 Nanomedicine -- 1.2 Evolution of Cancer Therapy -- 1.2.1 Surgery and Adjuvant Therapies -- 1.2.2 Hormone Therapy -- 1.2.3 Immunotherapy -- 1.2.4 Cancer Therapy with Nanomedicine -- 1.3 Nanoparticles in Cancer Therapy -- 1.3.1 Protein Nanoparticles -- 1.3.2 Magnetic Nanoparticles -- 1.3.3 Inorganic Nanoparticles -- 1.3.4 Lipid Nanoparticles -- 1.3.5 Targeted Nanoparticles -- 1.3.6 Polymeric Nanoparticles -- 1.3.7 Multifunctional Nanoparticles -- 1.3.8 Quantum Dots -- 1.3.9 DNA Nanoparticles -- 1.4 Pharmacokinetics of Cancer Nanodrug Carriers -- 1.5 Cancer Nanomedical Research -- 1.5.1 Initial Advancements in Nanoparticle Research -- 1.5.2 Nanomedical Research Using Plant-Derived Compounds -- 1.5.3 Nanomedical Research Using Gene Therapeutic Strategies -- 1.5.4 Nanomedical Research Using In Vivo Imaging Techniques -- 1.5.5 Mainstream Research in the ``Golden Age´´ of Nanotechnology -- 1.5.6 Nanomedical Research Using Computational and Nanobioinformatic Tools -- 1.6 Nanomedicine in Cancer Diagnosis and Treatment -- 1.6.1 Immunoassays Using Nanomaterial-Embedded Microchips -- 1.6.2 In Vivo Imaging Using Nanoparticle Contrast Agents -- 1.6.3 Theranostic Nanomedicine -- 1.6.4 Cancer Nanodrug Release Systems and Personalized Cancer Nanomedicine -- 1.7 Current Research and Prospects -- 1.7.1 Smart Nanocarrier-Based Drug-Delivery Systems for Cancer Therapy -- 1.7.2 RNA Delivery Using Nanoparticles -- 1.7.3 Nanobots -- 1.8 Concluding Remarks -- References -- 2: Strategies for Improving the Efficiency of Nanomaterials -- 2.1 Introduction -- 2.2 Strategies for the Improvement of Nanomaterials -- 2.2.1 Photocatalytic Efficiency -- 2.2.2 Therapeutic Efficiency.
2.2.2.1 Strategic Improvement of Nanomaterials for Enhanced Permeability and Retention (EPR) Effects -- 2.2.2.2 Strategic Improvement of Nanomedicine for Improved Drug Delivery Systems -- Liposome Based Nanoformulation -- Nanoemulsions -- Solid Lipid Nanoparticles (SLN) -- Strategies for Organelles Specific Targeting of Nanodrugs -- Virus Based Nanoformulation -- 2.2.2.3 Photoactivated Nanomaterials for Photodynamic and Photothermal Therapy (PDT/PTT) -- 2.2.2.4 Mesoporous Silica Nanoparticles (MSNP) -- 2.2.2.5 Dendrimers -- 2.2.3 Engineering Nanoparticles to Evade the Multidrug Resistance (MDR) in Cancer -- 2.2.4 Nanoparticle-Based Combination Therapy -- 2.3 Conclusion -- References -- 3: Bioinspired Nanoparticles in Cancer Theranostics -- 3.1 Introduction -- 3.2 Novelty of Bioinspired Nanoparticles Based Theranostics -- 3.2.1 Liposomes in Cancer Theranostics -- 3.2.2 Lipid Nanoparticles in Cancer Theragnostic -- 3.2.2.1 Solid Lipid Nanoparticles (SLNs) -- 3.2.2.2 Nano-Structured Lipids (NLCs) -- 3.2.2.3 Lipid Nanocapsules (LNCs) -- 3.2.3 Protein-Based Nanoparticles for Cancer Theranostics -- 3.2.4 Virus like Nanoparticles in Cancer Theranostics -- 3.2.5 Inorganic and Bionanoparticles in Cancer Theranostics -- 3.3 Conclusions and Future Perspectives -- References -- 4: Nanomedicines for Solid Tumors: Current Status, Challenges, and Future Prospects -- 4.1 Introduction -- 4.2 Possible Factors that Initiate Cancer Growth -- 4.2.1 Age -- 4.2.2 Cancer Causing Elements -- 4.2.3 Immunosuppression -- 4.2.4 Infectious Agents -- 4.2.5 Radiation -- 4.3 Tumor Classification Based on Tissue of Origin -- 4.4 Existing Treatment Options Available for Cancer -- 4.5 Description of Solid Tumor -- 4.6 Nanomedicine -- 4.6.1 Unlocking Novel Cancer Applications Exploited in the Field of Nanomedicine -- 4.7 Fabrications of Nanocarrier for Drug Delivery. 4.8 Targeted Delivery of Nanocarrires to the Tumor Niche as Well as Solid Tumor -- 4.8.1 Drug Targeting Mechanisms and Surface Functionalization of Nanocarriers Aiding Nanomedicine Based Technologies in Solid ... -- 4.9 Nanoscience Based Imaging Technologies in the Detection of Solid Tumors -- 4.9.1 Photodynamic Nanomedicine in the Treatment of Solid Tumors -- 4.10 Nanomedicine and Solid Tumor Heterogenecity -- 4.11 Nanomedicine in Solid Tumors: PROS and CONS? -- 4.11.1 PROS -- 4.11.2 CONS -- 4.12 Discussion -- 4.13 Future Perspective -- References -- 5: Nanomaterials for Early Cancer Diagnostics -- 5.1 Introduction -- 5.2 Cancer and Biomarkers -- 5.2.1 Early Detection of Prostate Cancer -- 5.2.2 Early Detection of Breast Cancer -- 5.2.3 Early Detection of Lung Cancer -- 5.2.4 Early Detection of Liver Cancer -- 5.2.5 Early Detection of Oral Cancer -- 5.2.6 Early Detection of Pancreatic Cancer -- 5.2.7 Early Detection of Ovarian Cancer -- 5.2.8 Early Detection of Human Cervical Cancer -- 5.2.9 Early Detection of Bladder Cancer -- 5.2.10 Early Detection of Head and Neck Cancer -- 5.2.11 Early Detection of Colon Cancer -- 5.3 Conclusion -- References -- 6: Role of Nanomedicine for Cancer Immunotherapy -- 6.1 Introduction -- 6.2 Improving Cellular-Mediated Immunotherapy -- 6.2.1 Combining Therapeutic Agents to Immune Cells -- 6.2.2 Directing Therapeutic Drugs to Immune Cells -- 6.2.3 Delivery of Gene in Lymphocytes -- 6.3 Delivery Mechanism of Nanoparticle Therapeutics -- 6.3.1 Stimulating Immunogenic Cell Death (ICD) -- 6.3.1.1 Nanosized Drug Carriers -- 6.3.1.2 Nanopulse Stimulation -- 6.3.2 Enhanced Presentation of Ligands to Immune Cells -- 6.3.3 Chronological Regulation of Immunostimulation -- 6.4 Modulation in Pharmacokinetics of Immunotherapy Agents -- 6.5 Targeting Myeloid Cells -- 6.6 Targeting Stromal Cell in TME. 6.7 Limitations of Nanomedicines in Cancer Immunotherapy -- 6.8 Conclusion and Future Perspectives -- References -- 7: Targeting Tumor Microenvironment Through Nanotheranostics -- 7.1 Introduction -- 7.2 The Tumor Microenvironment (TME) and its Components -- 7.2.1 Cells of the Immune System -- 7.2.1.1 The T Cells -- 7.2.1.2 The B Cells -- 7.2.1.3 Tumor Associated Macrophages (TAMs) -- 7.2.1.4 Tumor Associated Neutrophils (TANs) -- 7.2.1.5 Natural Killer (NK) Cells -- 7.2.1.6 Cancer Associated Fibroblasts (CAFs) -- 7.2.2 The Extracellular Matrix (ECM) and Surrounding Cells -- 7.2.2.1 The Adipocytes -- 7.2.2.2 The Pericytes -- 7.2.2.3 Matrix Metalloproteases (MMPs) and Other Proteases -- 7.2.2.4 The Endothelial Cells -- 7.2.3 The TME, Inflammation, and Cancer -- 7.2.4 Hypoxia in the TME -- 7.3 The TME as an Attractive Therapeutic Target in Cancer -- 7.4 Cancer Nanotheranostic Agents that Target the TME -- 7.4.1 Metallic Nanoparticles (NPs) -- 7.4.2 Magnetic Nanoparticles (MNPs) -- 7.4.3 Mesoporous Silica Nanoparticles (MSiNPs) -- 7.4.4 Nano-Graphenes (NGs) -- 7.4.5 Polymeric-Based Nanotheranostic Particles (PNPs) -- 7.4.6 Lipid-Based Nanotheranostic Particles (LNPs) -- 7.4.7 Protein-Based Nanotheranostic Particles (PNPs) -- 7.4.8 Viral-Based Nanotheranostic Particles (VLPs) -- 7.4.9 DNA-Based Cancer Nanotheranostic Platform -- 7.5 Visualizing Cancer Through Nanotheranostics -- 7.5.1 Magnetic Resonance Imaging (MRI) -- 7.5.2 Photoacoustic Imaging (PAI) -- 7.5.3 Optical Imaging -- 7.5.4 Nuclear Imaging -- 7.6 Nanotheranostics for the Detection of Cancer Biomarkers -- 7.6.1 Labeling Nanoparticles with Conjugates -- 7.6.1.1 Chemical Crosslinking -- 7.6.1.2 Biotin/Avidin Conjugation -- 7.6.1.3 Click Chemistry -- 7.6.2 Target Moieties for Identification of Cancer Biomarkers -- 7.7 Conclusion and Future Direction -- References. 8: Therapeutic Applications of Noble Metal (Au, Ag, Pt)-Based Nanomedicines for Melanoma -- 8.1 Introduction -- 8.1.1 Melanoma -- 8.1.1.1 Global Statistics and Market -- 8.1.1.2 Treatment Strategies -- 8.1.2 Nanotechnology in Melanoma -- 8.1.2.1 Nanoparticles for Melanoma -- 8.1.2.2 PAMAM -- 8.1.2.3 Zinc Oxide Nanoparticle -- 8.1.2.4 Titanium Dioxide Nanoparticle -- 8.1.2.5 Vanadium Pentoxide Nanoparticle -- 8.1.2.6 Copper Prussian Blue Nanoparticle -- 8.2 Importance of Noble Metal Nanoparticles in Biomedicine -- 8.3 Role of Noble Metals (Au, Ag, Pt) in Treatment of Melanoma -- 8.3.1 Gold (Au) Nanoparticles -- 8.3.1.1 Drug Delivery -- 8.3.1.2 Gene Delivery and Immunotherapy -- 8.3.1.3 Biosynthesized Gold Nanoparticles -- 8.3.1.4 Imaging -- 8.3.1.5 Photothermal and Photodynamic Therapy -- 8.3.2 Silver (Ag) Nanoparticles -- 8.3.3 Platinum (Pt) Nanoparticles -- 8.4 Toxicity of Noble Metal Nanoparticles -- 8.5 Challenges and Future Perspectives -- 8.6 Conclusion -- References -- 9: Ethics in Nanomedicine -- 9.1 Introduction -- 9.2 Nanomedicine -- 9.3 Difference Between Nanotechnology and Nanomedicine -- 9.4 Hype Versus Reality of Nanomedicine -- 9.5 Nondiscrimination and Integrity of Nanomedicine -- 9.6 The Potentiality of Nanomedicine -- 9.7 Biocompatibility and Toxicity of Nanostructures -- 9.8 Demand of the Nanomedicine in Market -- 9.9 Nanomedicine and Ethical Concerns -- 9.9.1 Ethical Problems Associated with Translational Research Involving Nanomedicine -- 9.9.2 Ethical Problems in Personalized and Regenerative Therapy with Nanomedicine -- 9.9.3 Ethical Concerns of Medical Surveillance -- 9.9.4 Ethical Challenges Inherent to Nanomedicine Applications -- 9.9.5 Social Ethics in Public Health Systems -- 9.9.5.1 Impact of Nanotechnology in Developing Nations -- 9.9.5.2 Impact of Nanotechnology on Laborers and Managerial Issues. 9.10 Future Perspectives. |
| Record Nr. | UNINA-9910488707403321 |
| Gateway East, Singapore : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Novel cancer-related biomarkers / / editors, Viktor Magdolen ... [et al.]
| Novel cancer-related biomarkers / / editors, Viktor Magdolen ... [et al.] |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Berlin, : De Gruyter, 2012 |
| Descrizione fisica | 1 online resource (242 p.) |
| Disciplina | 616.994075 |
| Altri autori (Persone) | MagdolenViktor |
| Collana | Kallikrein-related peptidases |
| Soggetto topico |
Tumor markers
Cancer - Diagnosis |
| Soggetto non controllato |
Biochemistry
Kallikrein Pathophysiology Peptidase Physiology |
| ISBN |
3-11-048153-7
3-11-030366-3 |
| Classificazione | WD 5065 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Frontmatter -- Preface -- List of contributing authors -- Table of Contents -- Introduction to Volume 2: Kallikrein-related Peptidases. Novel Cancer-related Biomarkers / Schmitt, Manfred / Sommerhoff, Christian P. / Fritz, Hans / Magdolen, Viktor -- 1 Pathophysiology of Kallikrein-related Peptidases in Lung Cancer / Heuzé-Vourc'H, Nathalie / Courty, Yves -- 2 Clinical Relevance of Kallikrein-related Peptidases in Gastric and Colorectal Cancer / Talieri, Maroulio / Devetzi, Marina / Schmitt, Manfred -- 3 Pathophysiology of Kallikrein-related Peptidases in Head and Neck Cancer / Jiang, Rong / Shi, Zonggao / Johnson, Jeffrey / Stack, M. Sharon -- 4 PSA (Prostate-Specific Antigen) and other Kallikrein-related Peptidases in Prostate Cancer / Koistinen, Hannu / Stenman, Ulf-Håkan -- 5 Cellular Model Systems to Study the Tumor Biological Role of Kallikrein-related Peptidases in Ovarian and Prostate Cancer / Dong, Ying / Loessner, Daniela / Sieh, Shirly / Taubenberger, Anna / Fuhrman-Luck, Ruth A. / Magdolen, Viktor / Hutmacher, Dietmar W. / Clements, Judith A. -- 6 Clinical Relevance of Kallikrein-related Peptidases in Breast Cancer / Schmitt, Manfred / Dorn, Julia / Kiechle, Marion / Diamandis, Eleftherios P. / Luo, Liu-Ying -- 7 Clinical Relevance of Kallikrein-related Peptidases in Ovarian Cancer / Dorn, Julia / Milou, Valentina / Kulasingam, Vathany / Schmalfeldt, Barbara / Diamandis, Eleftherios P. / Schmitt, Manfred -- 8 microRNAs: A New Control Mechanism for Kallikrein-related Peptidases in Kidney and Other Cancers / Yousef, George M. / White, Nicole M.A. -- 9 Genomic Instability of the KLK-locus in Cancer / Bayani, Jane / Diamandis, Eleftherios P. -- 10 Kallikrein-related Peptidases as Biomarkers in Personalized Cancer Medicine / Mavridis, Konstantinos / Schmitt, Manfred / Scorilas, Andreas -- Index |
| Record Nr. | UNINA-9910822066503321 |
| Berlin, : De Gruyter, 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Outcome prediction in cancer / / editors, Azzam F.G. Taktak and Anthony C. Fisher
| Outcome prediction in cancer / / editors, Azzam F.G. Taktak and Anthony C. Fisher |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Amsterdam ; ; Boston, : Elsevier, 2007 |
| Descrizione fisica | 1 online resource (483 p.) |
| Disciplina |
362.196994
616.994 616.994075 |
| Altri autori (Persone) |
TaktakAzzam F. G
FisherAnthony C., Dr. |
| Soggetto topico |
Cancer - Diagnosis
Cancer - Prognosis Neural networks (Computer science) Survival analysis (Biometry) |
| ISBN |
1-280-74728-5
9786610747283 0-08-046803-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front cover; Title page; Copyright page; Foreword; Table of Contents; Contributors; Introduction; Section 1: The Clinical Problem; Chapter 1: The Predictive Value of Detailed Histological Staging of Surgical Resection Specimens in Oral Cancer; 1. INTRODUCTION; 2. PREDICTIVE FEATURES RELATED TO THE PRIMARY TUMOUR; 3. PREDICTIVE FEATURES RELATED TO THE REGIONAL LYMPH NODES; 4. DISTANT (SYSTEMIC) METASTASES; 5. GENERAL PATIENT FEATURES; 6. MOLECULAR AND BIOLOGICAL MARKERS; 7. THE WAY AHEAD?; REFERENCES; Chapter 2: Survival after Treatment of Intraocular Melanoma; 1. INTRODUCTION
2. INTRAOCULAR MELANOMA3. STATISTICAL METHODS FOR PREDICTING METASTATIC DISEASE; 4. PREDICTING METASTATIC DEATH WITH NEURAL NETWORKS; 5. MISCELLANEOUS ERRORS; 6. A NEURAL NETWORK FOR PREDICTING SURVIVAL IN UVEAL MELANOMA PATIENTS; 7. CAVEATS REGARDING INTERPRETATION OF SURVIVAL STATISTICS; 8. FURTHER STUDIES; 9. CONCLUSIONS; REFERENCES; Chapter 3: Recent Developments in Relative Survival Analysis; 1. INTRODUCTION; 2. CAUSE-SPECIFIC SURVIVAL; 3. INDEPENDENCE ASSUMPTION; 4. EXPECTED SURVIVAL; 5. RELATIVE SURVIVAL; 6. POINT OF CURE; 7. REGRESSION ANALYSIS; 8. PERIOD ANALYSIS 9. AGE STANDARDIZATION10. PARAMETRIC METHODS; 11. MULTIPLE TUMOURS; 12. CONCLUSION; REFERENCES; Section 2: Biological and Genetic Factors; Chapter 4: Environmental and Genetic Risk Factors of Lung Cancer; 1. INTRODUCTION; 2. LUNG CANCER INCIDENCE AND MORTALITY; 3. CONCLUSION; REFERENCES; Chapter 5: Chaos, Cancer, the Cellular Operating System and the Prediction of Survival in Head and Neck Cancer; 1. INTRODUCTION; 2. CANCER AND ITS CAUSATION; 3. FUNDAMENTAL CELL BIOLOGY AND ONCOLOGY; 4. A NEW DIRECTION FOR FUNDAMENTAL CELL BIOLOGY AND ONCOLOGY 5. COMPLEX SYSTEMS ANALYSIS AS APPLIED TO BIOLOGICAL SYSTEMS AND SURVIVAL ANALYSIS6. METHODS OF ANALYSING FAILURE IN BIOLOGICAL SYSTEMS; 7. A COMPARISON OF A NEURAL NETWORK WITH COX'S REGRESSION IN PREDICTING SURVIVAL IN OVER 800 PATIENTS; 8. THE NEURAL NETWORK AND FUNDAMENTAL BIOLOGY AND ONCOLOGY; 9. THE DIRECTION OF FUTURE WORK; 10. SUMMARY; REFERENCES; Section 3: Mathematical Background of Prognostic Models; Chapter 6: Flexible Hazard Modelling for Outcome Prediction in Cancer: Perspectives for the Use of Bioinformatics Knowledge; 1. INTRODUCTION; 2. FAILURE TIME DATA 3. PARTITION AND GROUPING OF FAILURE TIMES4. COMPETING RISKS; 5. GLMs AND FFANNs; 6. APPLICATIONS TO CANCER DATA; 7. CONCLUSIONS; REFERENCES; Chapter 7: Information Geometry for Survival Analysis and Feature Selection by Neural Networks; 1. INTRODUCTION; 2. SURVIVAL FUNCTIONS; 3. STANDARD MODELS FOR SURVIVAL ANALYSIS; 4. THE NEURAL NETWORK MODEL; 5. LEARNING IN THE CPENN MODEL; 6. THE BAYESIAN APPROACH TO MODELLING; 7. VARIABLE SELECTION; 8. THE LAYERED PROJECTION ALGORITHM; 9. A SEARCH STRATEGY; 10. EXPERIMENTS; 11. CONCLUSION; REFERENCES Chapter 8: Artificial Neural Networks Used in the Survival Analysis of Breast Cancer Patients: A Node-Negative Study |
| Record Nr. | UNINA-9910824564103321 |
| Amsterdam ; ; Boston, : Elsevier, 2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
